Methyl N-[1-({2-[5-(5-{4-[2-(1-{2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl)-1H-imidazol-5-YL]phenyl}-2-thienyl)-1H-imidazol-2-YL]-1-pyrrolidinyl}carbonyl)-2-methylpropyl]carbamate | 1256385-50-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Methyl N-[1-({2-[5-(5-{4-[2-(1-{2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl)-1H-imidazol-5-YL]phenyl}-2-thienyl)-1H-imidazol-2-YL]-1-pyrrolidinyl}carbonyl)-2-methylpropyl]carbamate
• 英文别名: methyl N-[(2S)-1-[(2S)-2-[5-[5-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]thiophen-2-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
• CAS: 1256385-50-8
• 化学式: C₃₈H₄₈N₈O₆S
• 分子量: 744.915
• InChiKey: DBRMBKQTCROUKP-KOUWNTBJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  53
• 可旋转键数：
  13
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  203
• 氢给体数：
  4
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  tert-butyl (2S)-2-[5-[4-[5-[2-[(2S)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]thiophen-2-yl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carboxylate 在 盐酸 、 水 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 18.0h， 生成 Methyl N-[1-({2-[5-(5-{4-[2-(1-{2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl)-1H-imidazol-5-YL]phenyl}-2-thienyl)-1H-imidazol-2-YL]-1-pyrrolidinyl}carbonyl)-2-methylpropyl]carbamate
  参考文献：
  名称：

  Synthesis and biological evaluation of new potent and selective HCV NS5A inhibitors

  摘要：

  NS5A inhibitors are a new class of direct-acting antiviral agents which display very potent anti-HCV activity in vitro and in humans. Rationally designed modifications to the central biphenyl linkage of a known NS5A series led to selection of several compounds that were synthesized and evaluated in a HCV genotype 1b replicon. The straight triphenyl linked compound 11a showed similar anti-HCV activity to the clinical compound BMS-790052 and a superior cytotoxicity profile in three different cell lines, with an EC50 value of 26 pM and a therapeutic index of over four million in an HCV replicon assay. This triphenyl analog warrants further preclinical evaluation as an anti-HCV agent. (C) 2012 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2012.03.089

文献信息

• [EN] ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX
  申请人：GILEAD SCIENCES INC

  公开号：WO2010132601A1

  公开（公告）日：2010-11-18

  The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  这项发明涉及抗病毒化合物，含有这种化合物的组合物，包括给予这种化合物的治疗方法，以及用于制备这种化合物的过程和中间体。
• SUBSTITUTED AZOLES, ANTIVIRAL ACTIVE COMPONENT, PHARMACEUTICAL COMPOSITION, METHOD FOR PREPARATION AND USE THEREOF
  申请人：Ivachtchenko Alexandre Vasilievich

  公开号：US20130253008A1

  公开（公告）日：2013-09-26

  The present invention relates to novel azoles, novel antiviral active components of the general formulas 1A and 1B, pharmaceutical composition, antiviral medicament, method for prophylaxis and treatment of viral diseases, particularly caused by hepatitis C viruses (HCV). In general formulas 1A and 1B wherein: solid lines with accompanying dotted lines ( ) represent ordinary bond or double bond, provided that one of them is an ordinary bond, the other one is double bond; X and Y accept various meanings, one of them is—nitrogen, the other—oxygen, sulfur or NH group; R 1 and R 2 —optionally the same radicals selected from 2-(R)- and (S)-substituted N-acyl pyrrolidine derivatives; N-methyl-N-[2-(R) and (S)-substituted 2,2-disubstituted acetamides; methyl[2-(R) and (S)-substituted ((methyl)amino)-(1-oxobutan-2-yl)-2-(R)-] and (S)-iso-propyl)-carbamates. A represents aliphatic C 2 -C 8 biradical; dioxane, cyclo- and bicycloaliphatic, alkyloxyalkyl, alkyloxyalkylenoxyalkyl, alkenyloxyalkyl, alkynyloxyalkyl biradicals and their thioanaloges; aryl and thiophene alkynylcycloalkyl, alkynyldioxane, alkynylaryl, alkylthiophene, alkenylthiophene and alkynylthiophene, alkyloxyaryl, alkenyloxyaryl, alkynyloxyaryl, alkylthioaryl, alkenylthioaryl, alkynylthioaryl, cycloalkylthiophene, aryldioxane and thiophenyldioxane biradicals. B represents: aliphatic C 2 -C 8 radical, including 1, 2 or 3 triple C≡C bonds; aryl and thiophene, alkynylcycloalkyl, alkynyldioxane, alkynylaryl, alkylthiophene, alkenylthiophene and alkynylthiophene, cycloalkylbenzene, 4-cycloalkylbiphenyl, bicycloalkylbenzene, 4-bicycloalkylbiphenyl, cycloalkylthiophene, aryldioxane and thiophenyldioxane radicals.

  本发明涉及新型唑类化合物，通式1A和1B的新型抗病毒活性成分，药物组合物，抗病毒药物，预防和治疗病毒性疾病的方法，特别是由丙型肝炎病毒（HCV）引起的疾病。在通式1A和1B中，其中：实线与伴随虚线（）表示普通键或双键，前提是其中一个是普通键，另一个是双键；X和Y接受各种含义，其中一个是氮，另一个是氧、硫或NH基团；R1和R2—可选地选择自2-(R)-和(S)-取代的N-酰基吡咯烷衍生物；N-甲基-N-[2-(R)和(S)-取代的2,2-二取代乙酰胺；甲基[2-(R)和(S)-取代的((甲基)氨基)-(1-氧代丁酰)-2-(R)-]和(S)-异丙基)-氨基甲酸酯。A代表脂肪族C2-C8双基；二氧六环、环和双环脂肪族、烷氧烷基、烷氧烷氧基烷基、烯烃氧烷基、炔烃氧烷基双基及其硫代物；芳基和噻吩炔基环烷基、炔基二氧六环、炔基芳基、烷基噻吩烯烯基、炔基噻吩、烷氧芳基、烯烃氧芳基、炔烃氧芳基、烷硫芳基、烯硫芳基、炔硫芳基、环烷基噻吩、芳基二氧六环和噻吩二氧六环双基。B代表：脂肪族C2-C8基，包括1、2或3个三重键C≡C键；芳基和噻吩、炔基环烷基、炔基二氧六环、炔基芳基、烷基噻吩、烯烃噻吩和炔基噻吩、环烷基苯、4-环烷基联苯、双环烷基苯、4-双环烷基联苯、环烷基噻吩、芳基二氧六环和噻吩二氧六环基。
• ANTIVIRAL COMPOUNDS
  申请人：Guo Hongyan

  公开号：US20120157404A1

  公开（公告）日：2012-06-21

  The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  该发明涉及抗病毒化合物、含有这些化合物的组合物以及包括给予这些化合物的治疗方法，还涉及用于制备这些化合物的过程和中间体。
• SUBSTITUTED AZOLES, ANTI-VIRAL ACTIVE INGREDIENT, PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF
  申请人：Ivachtchenko, Alexandre Vasilievich

  公开号：EP2657231A2

  公开（公告）日：2013-10-30

  The present invention relates to novel azoles, novel antiviral active components of the general formulas 1A and 1B, pharmaceutical composition, antiviral medicament, method for prophylaxis and treatment of viral diseases, particularly caused by hepatisis C viruses (HCV). In general formulas 1A and 1B wherein: solid lines with accompanying dotted lines (---) represent ordinary bond or double bond, provided that one of them is an ordinary bond, the other one is double bond; X and Y accept various meanings, one of them is - nitrogen, the other - oxygen, sulfur or NH group; R1 and R2 - optionally the same radicals selected from 2-(R)- and (S)- substituted N-acyl pyrrolidine derivatives; N-methyl-N-[2-(R) and (S)- substituted 2,2-disubstituted acetamides; methyl[2-(R) and (S)-substituted ((methyl)amino)-(1-oxobutan-2-yl)-2-(R)-] and (S)-iso-propyl)-carbamates. A represents aliphatic C2-C8 biradical; dioxane, cyclo- and bicycloaliphatic, alkyloxyalkyl, alkyloxyalkylenoxyalkyl, alkenyloxyalkyl, alkynyloxyalkyl biradicals and their thioanaloges; aryl and thiophene alkynylcycloalkyl, alkynyldioxane, alkynylaryl, alkylthiophene, alkenylthiophene and alkynylthiophene, alkyloxyaryl, alkenyloxyaryl, alkynyloxyaryl, alkylthioaryl, alkenylthioaryl, alkynylthioaryl, cycloalkylthiophene, aryldioxane and thiophenyldioxane biradicals. B represents: aliphatic C2-C8 radical, including 1,2 or 3 triple C≡C bonds; aryl and thiophene, alkynylcycloalkyl, alkynyldioxane, alkynylaryl, alkylthiophene, alkenylthiophene and alkynylthiophene, cycloalkylbenzene, 4-cycloalkylbiphenyl, bicycloalkylbenzene, 4-bicycloalkylbiphenyl, cycloalkylthiophene, aryldioxane and thiophenyldioxane radicals.

  本发明涉及新型唑类、通式 1A 和 1B 的新型抗病毒活性成分、药物组合物、抗病毒药物、预防和治疗病毒性疾病（尤其是由丙型肝炎病毒（HCV）引起的疾病）的方法。在通式 1A 和 1B 中 其中实线和附带的虚线（----）代表普通键或双键，条件是其中一个是普通键，另一个是双键；X 和 Y 有多种含义，其中一个是氮，另一个是氧、硫或 NH 基团；R1和R2--任选相同的基团，选自 2-(R)-和(S)-取代的 N-酰基吡咯烷衍生物；N-甲基-N-[2-(R)-和(S)-取代的 2,2-二取代乙酰胺；甲基[2-(R)-和(S)-取代的((甲基)氨基)-(1-氧代丁-2-基)-2-(R)-]和(S)-异丙基)-氨基甲酸酯。A 代表脂肪族 C2-C8 双烷基；二噁烷、环脂族和双环脂族、烷氧基烷基、烷氧基烯氧基烷基、 烯氧基烷基、炔氧基烷基双烷基及其硫代类似物；芳基和噻吩炔基环烷基、炔基二氧杂环烷基、炔基芳基、烷基噻吩、烯基噻吩和炔基噻吩、烷氧基芳基、烯基氧基芳基、炔基氧基芳基、烷基硫代芳基、炔基硫代芳基、环烷基噻吩、芳基二氧杂环烷和噻吩二氧杂环烷双烷基。B 代表：脂肪族 C2-C8 自由基，包括 1、2 或 3 个三 C≡C 键；芳基和噻吩、炔基环烷基、炔基二氧杂环烷基、炔基芳基、炔基噻吩、烯基噻吩和炔基噻吩、环烷基苯、4-环烷基联苯、双环烷基苯、4-双环烷基联苯、环烷基噻吩、芳基二氧杂环烷和噻吩二氧杂环烷自由基。
• Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for the production and use thereof
  申请人：Alla Chem, LLC.

  公开号：EP2808325A1

  公开（公告）日：2014-12-03

  The present invention relates to novel azoles, novel antiviral active components of the general formula 1A and a pharmaceutical composition for prophylaxis and treatment of viral diseases, particularly caused by hepatisis C viruses (HCV).

  本发明涉及新型唑类、通式 1A 的新型抗病毒活性成分和一种药物组合物，用于预防和治疗病毒性疾病，特别是由丙型肝炎病毒（HCV）引起的疾病。